Advances in T Cell-Based Cancer Immunotherapy
This special issue belongs to the section "Molecular Immunology".
Special Issue Information
Dear Colleagues,
T Cell-Based Immunotherapy for Cancer highlights recent advances in harnessing T lymphocytes to achieve durable and specific anti-tumor responses. Over the past decade, breakthroughs such as immune checkpoint blockade targeting Programmed cell death protein 1 (PD-1) and Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4), along with chimeric antigen receptor (CAR) T cell therapy, have transformed the treatment landscape for hematologic malignancies and selected solid tumors. Nevertheless, significant challenges remain, including T cell exhaustion, limited persistence, antigen escape, and the immunosuppressive tumor microenvironment.
This Special Issue brings together original research and comprehensive reviews that explore innovative strategies to enhance T cell efficacy, specificity, and safety. Topics include the molecular regulation of T cell activation and differentiation, engineering approaches to optimize CAR and TCR-T cells, mechanisms of resistance to immunotherapy, and combinatorial strategies integrating checkpoint inhibitors, cytokine modulation, or metabolic reprogramming. In addition, emerging insights from single-cell and multi-omics technologies are reshaping our understanding of T cell heterogeneity and functional states within tumors.
By integrating mechanistic discoveries with translational and clinical perspectives, this collection aims to provide a comprehensive overview of current progress and future directions in T cell-based cancer immunotherapy, ultimately advancing the development of more effective and durable treatments for patients.
Dr. Ying Luo
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the Special Issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- T cell immunotherapy
- CAR-T cell
- immune checkpoint blockade
- T cell exhaustion
- tumor microenvironment
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

